(Q40086940)

17 September 2017

Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis (English)

1 reference

17 September 2017

0 references

1 reference

Schmit JL

1

1 reference

17 September 2017

Hary L

2

1 reference

17 September 2017

Bou P

3

1 reference

17 September 2017

Renaud H

4

1 reference

17 September 2017

Westeel PF

5

1 reference

17 September 2017

Andrejak M

6

1 reference

17 September 2017

Fournier A

7

1 reference

17 September 2017

language of work or name

English

0 references

publication date

1 July 1991

1 reference

17 September 2017

3

1 reference

Antimicrobial Agents and Chemotherapy

inferred from page(s)

published in

1 reference

17 September 2017

35

1 reference

17 September 2017

7

1 reference

17 September 2017

1492-1494

1 reference

Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans

17 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=245198

Microbiologic aspects of chronic ambulatory peritoneal dialysis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=245198

Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=245198

Drug therapy in continuous ambulatory peritoneal dialysis patients

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=245198

Inhibition of norfloxacin absorption by antacids

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=245198

The comparative in-vitro activity of pefloxacin.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=245198

Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=245198

Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies

4 November 2018

1 reference

12 December 2020

Cefotaxime and desacetyl cefotaxime kinetics in renal impairment

1 reference

12 December 2020

Reduced enteral absorption of ciprofloxacin in the presence of antacids

1 reference

12 December 2020

Improved high-performance liquid chromatographic determination of pefloxacin and its metabolite norfloxacin in human plasma and tissue

1 reference

12 December 2020

Pharmacokinetics of pefloxacin in renal insufficiency

1 reference

12 December 2020

Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers

1 reference

12 December 2020

Peritonitis in continuous ambulatory peritoneal dialysis: analysis of an 8-year experience

1 reference

12 December 2020

[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]

1 reference

12 December 2020

Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment

1 reference

12 December 2020

Pharmacokinetics of pefloxacin in normal and impaired renal function

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.35.7.1492

1 reference

17 September 2017

1 reference

17 September 2017

PubMed publication ID

1929314

1 reference